Cookies on this website

We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies.

Continue Find out more

Partner news

04 Jun 2014 arGEN-X enters long-term strategic alliance with Shire Pharmaceuticals in therapeutic antibodies
13 Jan 2014 arGEN-X receives two preclinical milestone payments under collaboration with Shire
08 May 2013 Nimbus Discovery announces agreement with Shire to co-develop therapies for rare diseases
07 Jan 2013 Ethris announces research based alliance on SNIM® modified RNA with Shire
07 Jan 2013 ArGEN-X expands its therapeutic antibody alliance with Shire
18 Dec 2012 Arrowhead and Shire Enter into Collaboration and License Agreement to Develop Peptide-Targeted Therapeutics
29 Feb 2012 arGEN-X enters into a therapeutic antibody alliance with Shire
09 May 2011 Heptares Grants Shire an Exclusive Option to License Novel Adenosine A2A Antagonist
24 Aug 2009 Santaris Pharma A/S forms strategic alliance with Shire plc to develop RNA-based medicines for the treatment of rare genetic disorders
09 Apr 2009 DSM announces long-term supply agreement with Shire
30 Mar 2009 Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of AmigalTM for Fabry Disease at ACMG 2009 Annual Meeting
04 Aug 2008 Noven Announces Triggering of $25million DAYTRANA® Sales Milestone
24 Oct 2007 Shire Chooses Capgemini as Global IT Partner
11 Oct 2007 Renovo wins European Biotechnica Award 2007
20 Apr 2007 Yale University School of Medicine - Brain Networks Strengthened by Closing Ion Channels (21KB PDF)
14 Feb 2007 Launch of " Replagal® 3.5 mg "for Anderson-Fabry Disease in Japan

Our global reach

Our products are marketed in over 50 countries worldwide, and we now have offices in 29 countries. View our interactive map, and learn more
about our global reach.

Our locations


Keep up to speed with Shire's latest news by checking out our press release section.

Press releases